Form 4: Halozyme Therapeutics Executive Receives Stock Award

Halozyme Therapeutics, Inc. reports an interim CFO, David A. Ramsay, received a stock award of 10,000 units.

Summary

• David A. Ramsay, Interim CFO of Halozyme Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on April 1, 2026.
• The RSUs will vest in full on June 30, 2026, contingent upon Mr. Ramsay remaining employed by the company until that date.
• Following vesting, there is a one-year holding period from the vesting date.
• The transaction was reported on April 2, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard executive compensation award rather than a significant strategic or financial development.

Positives

• Grant of 10,000 Restricted Stock Units to the Interim CFO, indicating a form of incentive and retention.
• The stock award vests in full on a specific future date, providing a clear target for continued employment.
• A one-year holding period post-vesting aligns the executive's interests with long-term shareholder value.

Risks

• The vesting of the stock award is contingent on the Reporting Person remaining employed through June 30, 2026, meaning departure before this date would result in forfeiture.
• The one-year holding period from the vesting date means the executive cannot sell the shares until after June 30, 2027, potentially limiting immediate liquidity.

Future Outlook

The future outlook for the stock award is tied to the continued employment of David A. Ramsay through June 30, 2026, after which the award vests and is subject to a one-year holding period.

Industry Context

StockSavvy.ai notes that the issuance of Restricted Stock Units (RSUs) to key executives like an Interim CFO is a common practice in the biotechnology and pharmaceutical sectors to incentivize performance and retain talent during critical periods.

Management Changes

Stakeholder Impact

• Shareholders: The award aligns executive interests with long-term shareholder value through the vesting and holding periods, but does not immediately impact share count or value.
• Employees: May signal a commitment to retaining key leadership, potentially contributing to stability.
• Management: The Interim CFO receives an incentive tied to continued employment and company performance.

Next Steps

• David A. Ramsay must remain employed by Halozyme Therapeutics, Inc. until June 30, 2026, for the RSUs to vest.
• The RSUs will be subject to a one-year holding period after vesting, meaning they cannot be sold until after June 30, 2027.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Form 4, Stock Award, Restricted Stock Units, RSU, Executive Compensation, Interim CFO, Insider Trading, Beneficial Ownership